Author

Kathleen J. Yost

Observed names: K Yost, K. Yost, Kathleen Yost Butler

Institution: Mayo Clinic

Observed institutions: University of North Carolina at Chapel Hill, Mayo Clinic, University of California San Diego, Sarah Cannon, Dana-Farber Cancer Institute, Tennessee Oncology, Vanderbilt-Ingram Cancer Center

ORCID: 0009-0004-3779-1886

Observed ORCID: 0009-0004-3779-1886

OpenAlex ID: A5066625420

Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial

2005 · D. L. Shipley, F. A. Greco, et al. · Journal of Clinical Oncology · 44

Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial

2005 · D. R. Spigel, J. D. Hainsworth, et al. · Journal of Clinical Oncology · 39

Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial

2005 · J. D. Hainsworth, J. A. Sosman, et al. · Journal of Clinical Oncology · 27

Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

2024 · Francis P. Worden, Evan Pisick, et al. · JCO Precision Oncology · 6

Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study

2024 · Gordan Srkalovic, Michael Rothe, et al. · JCO Precision Oncology · 3

Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Patients with Advanced Transitional Cell Carcinoma of the Urothelium

2006 · J.D. Hainsworth, A.A. Meluch, et al. · The Journal of Urology · 2

P91 Gemcitabine, epirubicin, and docetaxel (GED) asneoadjuvant therapy. Updated results from a multicenter phase II trial in locally advanced breast cancer

2005 · D. Yardley, P. Whitworth, et al. · The Breast · 1

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE

2026 · Katherine D Crew, Garnet L Anderson, et al. · JNCI Journal of the National Cancer Institute

Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

2026 · Evan Pisick, Michael Rothe, et al. · JCO Precision Oncology

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

2026 · Erin F. Cobain, Michael Rothe, et al. · JCO Precision Oncology

Minimal important differences to assess cross-sectional differences among groups and minimal important changes to assess longitudinal within-patient changes for the Mayo Clinic Vestibular Schwannoma Quality of Life Index

2026 · Matthew L. Carlson, Christine M. Lohse, et al. · Journal of neurosurgery

A nationwide double-blind phase III randomized clinical trial (RCT) of olanzapine vs. prochlorperazine for the treatment of refractory nausea in patients receiving moderately or highly emetogenic chemotherapy among NCI Community Oncology Research Program (NCORP) practices.

2024 · Luke Joseph Peppone, Chunkit Fung, et al. · JCO Oncology Practice

Abstract P1-12-10: Regimen-specific rates of chemotherapy-related amenorrhea in breast cancer survivors

2019 · KC Gast, EJ Cathcart-Rake, et al. · Cancer Research

Works count: 13

Citation count: 122

H-index: 4

I10-index: 3